Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219180 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,797
- Enrollment target
NCT00219180: Completed Phase 3 study, sponsored by Novartis.
NCT00219180 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,797 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219180, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,797 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,797 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00219180 record still lists
NCT00219180 is an interventional study that assigns participants to a tested intervention. Its 1,797 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00219180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219180 about?
NCT00219180 is a clinical study titled "Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure". To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
What is the current status of trial NCT00219180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,797 participants. The study started on 2005-06. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00219180?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219180?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00219180's enrollment target sits among peer trials
1,797 125th of 2000 higher than 1,876 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia